Molecular Partners AG — Company profile
Healthcare · Biotechnology · Switzerland
Last price 3.53 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 138.60M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Details
| Name | Molecular Partners AG |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 134 |
| Founded | 2004 |
| Ipo Date | 2021-06-16 |
| Ceo | Patrick Amstutz |
| Country | Switzerland |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| Ipo Price | 21.25 |
| Isin | US60853G1067 |
| Cusip | 60853G106 |
| Cik | 1745114 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Patrick Amstutz Ph.D. | Co-Founder, Chief Executive Officer, Member of Management Board and Director |
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive Vice President of Projects and Member of Management Board |
| Robert Hendriks | Senior Vice President of Finance and Member of Management Board |
| Alexander Zurcher | Chief Operating Officer and Member of Management Board |
| Renate Gloggner | Executive Vice President of People and Community and Member of Management Board |
| Dr. Philippe Legenne M.B.A., M.D. | Chief Medical Officer and Member of the Management Board |
| Martin Steegmaier Ph.D. | Chief Scientific Officer and Member of the Management Board |
| Michael Pitzner | Executive Vice President of Partnering and General Counsel |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant |
| Daniel Steiner Ph.D. | Senior Vice President of Targeted Radio Therapeutics |
Contact
| Address | Wagistrasse 14, Schlieren, 8952, Switzerland |
| Phone | 41 44 755 77 00 |
| Website | https://www.molecularpartners.com |